CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Acral pseudolymphomatous angiokeratoma of children (APACHE)-like eruption in adult identical twins.

Acral pseudolymphomatous angiokeratoma of children (APACHE) is a condition that was first described in 1990 in a group of children, but has since been described in adults. We present the cases of identical twin patients aged 40 years. The first brother presented with an 8-year history of itchy lesions over the left ankle and the insteps of both feet. After a diagnostic biopsy, he was treated with potent steroids under occlusion for 8 weeks, which resulted in flattening of the lesions and resolution of the pruritus. The second twin had a 20-year history of a very similar presentation but the lesions were less pronounced; he chose not to have treatment. No other family members were affected. Skin biopsies from both patients showed similar changes. Within an overall hyperkeratotic and acanthotic epidermis, there were focal areas of lichenoid change and epidermal thinning. Beneath these areas, there was oedema and nodular aggregates of dense inflammatory cell infiltrate, predominantly lymphocytic infiltrate. APACHE has not been previously described in twins.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app